rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

David F. Hale

Director

Company insider

Files Form 4 as: Director and 10% owner, Dermata Therapeutics; Director, Oncternal Therapeutics; Chairman, Biocept; Director, Conatus Pharmaceuticals; Director, Santarus; Executive Chairman, Pernix Sleep; President and CEO, Micromet; Director, Metabasis Therapeutics.

Every Form 4 they filed

In numbers

Trades disclosed
281
Buys
10
Sells
6
Bought
$406K
Sold
$778K
Companies
8
Companies where not an officer
5
First trade
15 Dec 2005
Last trade
2 Jan 2026
Last filed
6 Jan 2026

Companies traded

Where they are an officer
BioceptDirector, Officer · last 9 Dec 20213 buys · 2 sells
Pernix SleepDirector, Officer · last 6 Mar 20130 buys · 1 sell
MicrometDirector, Officer · last 7 Mar 20121 buy · 2 sells
Everywhere else they filed: board seats, 10% stakes, other companies
DRMA Dermata TherapeuticsDirector, 10% owner · Biotechnology · last 2 Jan 20261 buy · 0 sells
Oncternal TherapeuticsDirector · last 20 Jun 20242 buys · 1 sell
Conatus PharmaceuticalsDirector · last 27 Jun 20191 buy · 0 sells
SantarusDirector · last 2 Jan 20141 buy · 0 sells
Metabasis TherapeuticsDirector · last 23 Jun 20091 buy · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
101Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
2 Jan 2026filed 6 Jan 2026DRMA Dermata Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—2,500 at $0.00filing
2 Jan 2026filed 6 Jan 2026DRMA Dermata Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—2,500 at $0.00filing
23 Jan 2025filed 23 Jan 2025DRMA Dermata TherapeuticsBiotechnologySEC FORM 4 Code A—78,741filing
21 Jan 2025filed 23 Jan 2025DRMA Dermata Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—78,741filing
13 Jan 2025filed 14 Jan 2025DRMA Dermata Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—5,000 at $0.00filing
20 Jun 2024filed 24 Jun 2024Oncternal Therapeuticsoption or derivativeSEC FORM 4 Code A—3,300 at $0.00filing
23 Feb 2024filed 27 Feb 2024Oncternal TherapeuticsSEC FORM 4 Bought$6,455714 at $9.04filing
23 Feb 2024filed 27 Feb 2024Oncternal TherapeuticsSEC FORM 4 Bought$2,405266 at $9.04filing
4 Jan 2024filed 5 Jan 2024DRMA Dermata Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—10,000 at $0.00filing
28 Jun 2023filed 30 Jun 2023Oncternal Therapeuticsoption or derivativeSEC FORM 4 Code A—37,500 at $0.00filing
6 Oct 2022filed 7 Oct 2022DRMA Dermata TherapeuticsBiotechnologySEC FORM 4 Code A—30,155 at $0.00filing
7 Jul 2022filed 8 Jul 2022DRMA Dermata TherapeuticsBiotechnologySEC FORM 4 Code A—26,441 at $0.00filing
16 Jun 2022filed 17 Jun 2022Oncternal Therapeuticsoption or derivativeSEC FORM 4 Code A—37,500 at $0.00filing
7 Apr 2022filed 8 Apr 2022DRMA Dermata TherapeuticsBiotechnologySEC FORM 4 Code A—15,466 at $0.00filing
3 Jan 2022filed 5 Jan 2022DRMA Dermata Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—5,000 at $0.00filing
9 Dec 2021filed 10 Dec 2021BioceptSEC FORM 4 Sold$1,474363 at $4.06filing
9 Dec 2021filed 10 Dec 2021BioceptSEC FORM 4 Sold$4511 at $4.07filing
9 Dec 2021filed 10 Dec 2021BioceptSEC FORM 4 Sold$28971 at $4.07filing
1 Oct 2021filed 11 Feb 2022Oncternal TherapeuticsSEC FORM 4 Code G—125,000 at $0.00filing
17 Aug 2021filed 17 Aug 2021DRMA Dermata Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—302,112 at $0.00filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Health Care1
Not placed15

Buys in green, sells in red, by the company’s sector.

Related people

Nobody else traded the same names lately.